Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Kudos To Adam Feurstein, For Once...

|Includes: Amarin Corporation PLC (AMRN), AZN, GSK

For once, AF steps up to correct a near-criminal statement by Summer Street (not AF), a known-short seller of Amarin shares. Hopefully, he can keep up reporting accurate, useful information.

I have said for some time, FDA will approve the Anchor indication in December, and they will. GSK and now AZN have no answer to Anchor, and that's a big deal. Neither one of their therapies effectively reduce TG levels as pure EPA in the 200-500 population. This is proven by no dose dependent effect by Epanova (huge trouble) and the fact that for more than 7 years GSK has never expanded Lovaza--because they know it doesn't work in Anchor.

If AF wants to take the stance that he does not believe they will get approval in December, that's fine and if he states his position, no issue respecting and disagreeing with it. But, Summer Street will now be getting serious SEC inquiries and I am already hearing quite serious trouble will be brewing as their position in Amarin has been under investigation.